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Abstract: The bacterial RecA protein has been implicated as a bacterial drug target not as an antimicrobial target, but as 
an adjuvant target with the potential to suppress the mechanism by which bacteria gain drug resistance. In order to iden-
tify small molecules that inhibit RecA/ssDNA nucleoprotein filament formation, we have adapted the phosphomolybdate-
blue ATPase assay for high throughput screening to determine RecA ATPase activity against a library of 33,600 com-
pounds, which is a selected representation of diverse structure of 350,000. Four distinct chemotypes were represented 
among the 40 validated hits. SAR and further chemical synthesis is underway to optimize this set of inhibitors to be used 
as antimicrobial adjuvant agents. 
Keywords: Antibiotic resistance, ATPase inhibition, high throughput screening, microbial drug resistance, RecA, SOS   
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INTRODUCTION 
  Antibiotic resistance is an innate problem involved in the 
treatment of bacterial infectious diseases and the incidence 
of these infections is escalating at an alarming rate [1-3]. 
Resistance not only renders current antibiotics useless 
against dangerous pathogens, but it is also a financial deter-
rent to efforts towards the discovery of novel antibiotics [4]. 
As a result, many pharmaceutical companies have reduced or 
eliminated their antibacterial drug discovery efforts [5], and 
since 1962 only three new classes of antibacterial agents 
have been introduced [6]. Genomics-driven discovery 
against targets considered essential has not yielded any clini-
cally approved drugs [5], and one way to avert this looming 
public health crisis could be to replenish antibiotic drug 
pipelines with drugs against targets not considered essential 
for survival. In fact, two-thirds of Escherichia coli genes fall 
into this population [7], and targeting this previously ignored 
segment of the bacterial genome may offer possibilities for 
the discovery of non-traditional pharmaceutical agents that 
attenuate pathogenicity [8] or potentiate the pharmacologic 
effects of known antibacterial agents [9]. In this context, we 
have focused on the bacterial RecA protein as a prospective 
target in the treatment of bacterial infectious diseases. 
RecA’s activities are central to the repair of DNA damage 
and stalled replication, but are also important for adaptive 
mutagenesis and horizontal gene transfer. We hypothesize 
that small molecule inhibitors of RecA may sensitize bacte-
ria to established antibacterial agents and prevent the devel-
opment and acquisition of genes conferring drug resistance. 
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 In  Escherichia coli, a model system to study DNA dam-
age, RecA’s expression is upregulated by events that chal-
lenge the integrity of the organism’s genome, and lead to the 
formation of single-stranded DNA (ssDNA), a hallmark of 
DNA damage [10]. In this event, RecA monomers respond 
by forming a homopolymer on the exposed ssDNA, initiat-
ing a series of programmed events that can be fundamentally 
associated with two major functions, de-repression of the 
SOS regulon and recombinational DNA strand exchange [11, 
12]. In the first function, the SOS regulon is initiated when 
the RecA nucleoprotein filament comes into contact with the 
LexA repressor, which sits on promoters of up to 40 genes 
that are involved in repairing DNA damage [13]. Gene prod-
ucts expressed in the early stages of SOS repair the DNA 
damage by nucleotide excision (e.g., UvrABCD) or recom-
bination (e.g., RecA), while gene products of the late stages 
of SOS are involved in error-prone DNA synthesis (e.g., 
PolIV and PolV) that systematically introduces mutations 
into the bacterial genome and facilitates adaptive evolution 
[14-17]. In the second function, RecA pairs ssDNA with 
homologous duplex DNA, and hydrolyzes ATP to induce the 
conformational rearrangements necessary to catalyze a 
strand exchange reaction that produces two new DNA mole-
cules [18, 19]. This ATPase-dependent activity is necessary 
for recombinational DNA repair [20, 21] and horizontal gene 
transfer during bacterial transformation, transduction and 
conjugation [22]. 
  Recently, the SOS and recombination processes mediated 
by RecA have been shown to be activated in response to 
antibiotic treatment [23-25]. The biological activities con-
trolled by RecA likely enhance a bacterium’s tolerance to 
antibiotics and can result in the de novo development and 
horizontal transfer of antibiotic resistance genes. Because 
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therapy are highly conserved among bacteria, small molecule 
modulators of RecA would be valuable for further explora-
tion of its roles in bacterial pathogens and its potential ex-
ploitation as a therapeutic target. While ATP-competitive 
nucleotide analogs [26, 27], polysulfated naphthyl com-
pounds [28], short alpha-helical peptides [29] and select 
transition metal cations [30] are effective inhibitors of RecA 
in vitro, none of these molecular classes have demonstrated 
RecA-specific biological activities in bacterial cell cultures. 
  Towards the goal of discovering potent cell-permeable 
inhibitors for the validation of RecA as an important and 
novel target for the chemotherapeutic treatment of bacterial 
infections, we carried out a two-tiered HTS campaign 
against RecA. As ssDNA-dependent ATP hydrolysis is a 
useful indicator that the RecA protein is active, we elected to 
screen the compounds using an inexpensive, yet robust and 
reliable phosphomolybdate blue ATPase assay to identify 
compounds that inhibit ATP hydrolysis. We initially 
screened the BRITE diversity set, which is comprised of 
approximately 10% of our proprietary collection of nearly 
350K compounds selected to maximize chemical diversity. 
From this collection, we identified 40 hits that clustered into 
four chemotype classes which were then carried into dose-
response confirmatory testing. We have also performed 
Tanimoto-based similarity searching in the entire BRITE 
library to identify related compounds that will be screened to 
provide initial insights into structure-activity relationships.  
MATERIALS AND METHODOLOGY 
RecA and ATPase Reagents 
  For the single-concentration screening, RecA protein was 
purified and stored as previously described by Singleton,   
et al. [31] and for additional screen of 8640 compounds, the 
enzyme was purchased from Epicentre Biotechnologies for 
the dose/response study. The commercially available enzyme 
has similar purity and specific activity as purified in-house, 
which is greater than 90% pure as judged by SDS-PAGE. 
Polydeoxythymidylic Acid (poly(dT)) single-strand DNA 
(average length = 300 nucleotides) was purchased from Mid-
land Certified Reagent Company (Cat #P-2004, Lot 110607-
403). Crystalline L-ascorbic acid and sulfuric acid were pur-
chased from Fisher Scientific. Unless otherwise stated all 
other reagents were purchased from Sigma-Aldrich at the 
highest level of purity possible.  
Compound Libraries and Handling  
  The general strategy for RecA screening was to test a 
small diverse library and then elaborate on the confirmed 
active compounds by similarity searching in the entire 
BRITE compound library. The BRITE diversity library 
screened in this HTS effort consists of 33,600 compounds 
selected for chemical diversity from the entire BRITE li-
brary, which was generated by combinatorial chemistry syn-
thetic routes and was a gift from Biogen-Idec in 2005. All of 
the compound plates were stored in polypropylene deep-well 
blocks at 4 °C without humidity controls. The BRITE com-
pound library is plated in 384-well Greiner V-bottom poly-
propylene plates in 100% DMSO in 10 mM and 1 mM ali-
quots. Plates are stored at 4 
oC. Using the Biomek
® NX and 
P20 tips, 0.5 l of 1 mM compound in DMSO was spotted 
into columns 3 - 22 of Costar clear flat bottom 384-well as-
say plates (Corning # 3702) for single shot analysis. Col-
umns 1, 2, 23, and 24 were spotted with 0.5 l of DMSO 
with the Biomek
® NX and P20 tips and used as positive and 
negative controls. This resulted in a final concentration of 10 
M for single-point screening. 
 For  dose-response/IC50 curve analysis, 1 l of the 10 mM 
stock of selected compounds was added to 4 l of DMSO 
and mixed in an Axygen 384-well PCR plate for a 5-fold 
dilution and beginning concentration of 2 mM. This was 
performed with the Biomek
® 3000 and P20 tips. A 10-point 
2-fold serial dilution was then performed across the plate 
with the Biomek
® 3000. The serially diluted compounds 
were then spotted to columns 3 – 22 of Costar clear flat bot-
tom 384-well assay plates with the Biomek
® NX and P20 
tips. Columns 1, 2, 23, and 24 were spotted with 0.5 l of 
DMSO with the Biomek
® NX and P20 tips and used as posi-
tive and negative controls.  
Phosphomolybdate-Blue ATPase Assay 
  A modified phosphomolbydate-blue ATPase assay (Un-
published data; Yeh L.A.) was used to quantify the amount 
of free phosphate as a measure of ATP hydrolysis, as an in-
direct measure of RecA nucleoprotein filament assembly 
[32]. The ATPase reactions were carried out in Costar clear 
flat-bottom 384-well assay plates (Corning, Lowell, MA) 
that the compounds were spotted in, and the final volume in 
each well was 30.5 l, giving final concentrations of 17 M 
for the library compound and 1.6% for DSMO. A 2.25 M 
stock of ATP was prepared in H2O and 10 l of this was 
added to all wells of the assay plates using a Thermo Mu-
tidrop 384-well dispenser (Thermo Fisher, Waltham, MA), 
yielding a final ATP concentration of 0.75 M. The reaction 
rate is linear at this low ATP concentration. The assay de-
velopment, optimization and validation studies of known 
compounds were described in a recent publication by Wigle 
[33]. After assay assembly, the plates were then incubated at 
room temperature for 15 min. To columns 3-24 of the assay 
plates, using a Thermo Mutidrop 384-well dispenser, was 
added 20 l of a cocktail of containing 0.5 M RecA, 5 M 
poly(dT) ssDNA, 10 mM Mg(OAc)2, 25 M Tris·HOAc, and 
5% v/v glycerol. For the negative control (minimum signal 
control), 20 l of an identical solution omitting poly(dT)-
DNA was added to columns 1 and 2 using a Thermo Mu-
tidrop 384-well dispenser. The positive control (maximum 
signal control) in lanes 23 and 24 contained the full ATPase 
reaction reagents and 0.5 l DMSO representing the 
full/uninhibited RecA activity. Compounds that exhibited 
inhibition greater than 50% in the primary screen were car-
ried into the dose-response confirmation step.  
  For the IC50 determinations, the PMB ATPase assay was 
improved by the addition of 10 g /mL BSA to reduce the 
immobilization of RecA in the assay plates, thereby increas-
ing the amount of RecA in the well that can participate in 
nucleation and filament formation. It was also determined 
that the assay window was wider when the optical absorption 
was tabulated at 825 nm. Serial dilutions of compounds were 
performed in 100% DMSO with a two-fold dilution factor 
resulting in 10 final concentrations spanning 33 M to 65 
nM. The serially diluted compounds (0.5 L) were dry spot-
ted into assay plates and were assembled as described for the 
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gressions were performed and IC50 values were determined 
using the XLfit software (XLFit software, IDBS, Guildford 
UK).  
  The assay plates were sealed by a Thermo Scientific mi-
croplate heat sealer and centrifuged at 1000 RPM for 1 min. 
The plates were then transferred to a 37 ºC air incubator and 
the ATPase reaction was allowed to proceed for 35 min. The 
plates were subsequently removed from incubator and 30 l 
of freshly made phosphomolybdate blue dye (10% ascorbic 
acid and 2.5% ammonium molybdate at the ratio of 1:1 and 
adding 12 M sulfuric acid at 6.25% v/v) was added to all 
wells using a Thermo Mutidrop 384-well dispenser. After 30 
min of incubation at room temperature, the plates were 
scanned for absorbance at 825 nm using a Spectramax-384 
Plus (Molecular Devices, Sunnyvale, CA). 
HTS Results and RecA Inhibitor Identification 
  In lieu of direct measurement of RecA nucleoprotein 
filament formation, we chose a more HTS-amenable end-
point of ATP hydrolysis in the presence of single-stranded 
DNA to identify RecA inhibitors. Here we report confirmed 
molecular structures for the most potent RecA inhibitors in 
each distinct class discovered in this screening effort. This 
screening approach successfully identified several chemo-
type classes and gave initial insight into the structure-activity 
relationship of small molecule inhibition of bacterial RecA. 
RESULTS 
  The PMB ATPase screen of the BRITE diversity library 
resulted in 73 active compounds exhibiting RecA inhibition 
above a 50% threshold. RecA inhibitors were triaged by se-
lecting the most potent single-point hits and were confirmed 
with dose-response. The average Z for this screen was 0.83, 
with an overall hit rate of 0.22%. Of the 73 hits obtained, 71 
of 73 compounds could be classified into one of four chemo-
type classes based on structural similarity (Fig. 1). The label 
for chemotype classes D and C are reversed in the lower 
portion of Fig. (1). “C - 9 compounds” should appear on the 
lower left, and “D – 2 compounds” should appear on the 
lower right. 
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Fig. (1). Four chemotype classes of RecA inhibitors showing the 
number of compounds discovered for each classes in this PMB 
ATPase high thoughput screening effort. 
  The 73 hits identified in the single-point 10 M screen 
were carried into dose-response confirmation with 40 com-
pounds exhibiting dose-response behavior, yielding a 55% 
confirmation rate. A typical dose-response curve for RecA 
inhibitors is shown in Fig. (2), with characteristic steep dose-
response curve likely due to multi-site inhibitor binding and 
well known positive cooperative binding kinetics [34, 35]. 
The structure and dose-response curve for the most potent 
RecA inhibitor identified in the BRITE diversity set screen, 
BRITE-338733, is shown in Fig. (2) and has been analyzed 
and exhibits a 4.7M IC50 and a Hill slope of 7.6. The com-
pound BRITE-345133 (chosen as representative of the 2-
amino-4,6-diarylpyridine scaffold) has been analyzed by 
LC/MS and has a confirmed mass of 524.1 m/z (m+1 peak) 
and is 89% pure. The range of IC50 values for the 40 con-
firmed compounds is 4.7 M to 39 M and the average Hill 
slope is 7.4. The molecular structures and corresponding IC50 
values are shown in Table 1. The 2-amino-4,6-diarylpyridine 
scaffold is the most potent as shown by BRITE-338733 hav-
ing an IC50 of 4.7 M. The 1,2,4-oxadiazole scaffold of 
BRITE-212537 followed by the quinaxolinone scaffold of 
BRITE-379089 and the benzimidazole diazepinone scaffold 
of BRITE-082776 produced IC50 values of 6.2, 11 and 32 
M respectively, and represent the most potent members of 
their respective classes. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Dose-response curve for the RecA inhibitor BRITE-
338733, exhibiting an IC50 value of 4.7 ± 0.5 M and characteristic 
steep Hill-slope (> 5). 
 
DISCUSSION 
  Here we present a focused high throughput screening 
effort that effectively identified several novel RecA inhibi-
tors for molecular probes to investigate the impact of RecA 
inhibition on antibacterial drug resistance. Multiple chemical 
scaffolds were identified but the 2-amino-4,6-diarylpyridine 
scaffold was the most potent class of inhibitors. We have 
independently verified biological activity of this chemotype 
as described in Wigle, 2009 [33]. 
  The PMB ATPase assay, while not a direct measure of 
nucleoprotein filament formation, provides a valuable means 
for the identification of RecA inhibitors with excellent 
screening statistics and normal confirmation rates (see 
Wigle, 2009) [33]. We found the assay to be very robust; 
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Table 1.  Chemical Structures of Confirmed RecA Inhibitors 
A. Chemotype-A Structures, Sorted by Potency 
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A. Chemotype-A Structures, Sorted by Potency 
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A. Chemotype-A Structures, Sorted by Potency 
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C. Chemotype-C Structures, Sorted by Potency 
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D. Chemotype-D Structures, Sorted by Potency 
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however, the assay window and statistics could vary signifi-
cantly from RecA protein batch to batch. The cause of this 
variation was determined to be residual free phosphate from 
the protein purification process involving phosphate-based 
buffers. We routinely performed min-max experiments in 
one 384-well plate (half-min, half-max) to investigate the 
assay window and signal-to-noise ratio for batch validation 
and would dialyze the RecA protein in the assay buffer to 
reduce the amount of free phosphate. Excellent assay statis-
tics were achieved when the UV/Vis absorption assay win-
dow (max-minus-min) was above 0.2 for A650, and above 1.0 
for A825. Two changes were made upon reflection on the 
initial BRITE-diversity set screen prior to the confirmation 
step; 1) shifting absorption wavelength to 825 nm and 2) 
with the addition of 10 g/mL BSA, which resulted in an 
increase in Z from 0.83 to 0.90. 
 Typical  IC50 curves for RecA inhibition are steep, with fit 
Hill slopes typically above five. It is expected that positive 
cooperative binding (long known in the experimental RecA 
literature) would result in steep inhibitory Hill slopes. We 
have performed dynamic light scattering (DLS) experiments 
(Dynapro-384, Wyatt Tech. Santa Barbara, CA) to inde-
pendently assess if the 2-amino-4,6-diarylpyridine scaffold 
(class A, most potent overall) was aggregating RecA protein 
in the absence of DNA. We found no indication of RecA 
aggregation in the presence of up to 10 M BRITE-345133 
(chosen as representative of the 2-amino-4,6-diarylpyridine 
scaffold) with DLS, which is approaching the solubility limit 
for the compound (data not shown). These DLS experiments 
confirm that chemotype-A compounds are genuine RecA 
inhibitors and the kinetics of inhibition adhere to a multi-site 
kinetic model. The DLS data will be published in a separate 
manuscript. 
  The preliminary structure-activity-relationship of the 
additional 8640 compounds selected from the rest of the 
350,000 compound library for the active scaffolds shows a 
relatively flat profile, with most IC50 values hovering in the 
low micromolar range (data not shown). We believe that this 
PMB ATPase assay is not suitable for profiling the SAR 
because low micromolar concentrations are at the lower edge 
of the assay dynamic range. We are developing more sensi-
tive assays to adequately profile the SAR for these com-
pounds in the nano- to micromolar range.  
CONCLUSION 
  We have screened 33,600 compounds selected from a 
library containing 350,000 compounds. Here we present 40 
confirmed inhibitors of RecA ATPase activity. The 40 con-
firmed hits represented four novel scaffolds for RecA inhibi-
tion. These scaffolds will be used for future structure activity 
relation (SAR) analysis. Among the four scaffolds, the 2-
amino-4,6-diarylpyridine compounds are the most potent 
with IC50 values in the single-digit micromolar range. We are 
in the process of developing new sensitive assays to further 
the SAR exploration. This high-throughput screening effort 
effectively identified a diverse set of active chemical scaf-
folds to serve as molecular probes for studying the effects of 
RecA in the development of antimicrobial resistance. 
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